Page 70 - manuscript_ijb05590

Table 5. Summary of studies on 3D-printed microfluidic systems to capture tumor markers

Biomarke Microfluidic technology Results Advantages Reference
rs
CTCs RUBYchip™ The average capture efficiency of RCC cells Efficiently captures CTCs and Leitão et al. 125
is 74.9%, significantly higher than other remains unaffected by epithelial-
methods. mesenchymal transition (EMT)
Sorting by Interfacial Effectively isolates cancer cell Adjusts the pH selection threshold Zielke et al. 162
Tension (SIFT) subpopulations by altering fluid conditions
with high glycolytic activity.
A 3D-nanostructured The synergistic effect enhances CTC The micro-mixer function enhances Wang et al.
substrate coated with anti- capture performance observed in blood the interaction between cells and 122,123
EpCAM samples. the substrate's local topography
Using various downstream analyses Various labeled tumor cell lines can Cohen et al. 124
the Parsortix® PR1 system to enrich breast cancer cells be captured from the blood without
in a small volume of blood from healthy being restricted
donors. by surface antigens.
HA-functionalized Specifically captured CD44-overexpressing Enables non-destructive release of the Wang et al. 163
electrospun CNF-integrated cancer cells captured cells, facilitating subsequent
microfludic platform with a efficiency of up to 91% and achieve cell analysis.
90% complete cell release through
treatment with GSH.
Detecting CTCs in patients with cervical Allows for genomic amplification and Law et al. 126
V-BioChip cancer and endometrial cancer, the mutation analysis of individual CTCs,
expression of HER2 and GATA3 in CTCs is offering potential for personalized
highly associated with early recurrence. treatment.

63